COMMITMENTS AND CONTINGENCIES (Details Narrative)
$ / shares in Units, € in Millions |
|
|
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
|
|
|
Jul. 01, 2025
shares
|
Jan. 16, 2025
EUR (€)
shares
|
Jan. 01, 2024
USD ($)
|
Dec. 20, 2023
Integer
|
Aug. 01, 2023
USD ($)
shares
|
Aug. 31, 2025
USD ($)
|
Aug. 31, 2024
USD ($)
|
Apr. 30, 2022
USD ($)
$ / shares
shares
|
May 31, 2020
USD ($)
|
Oct. 31, 2019
USD ($)
|
Jul. 31, 2019
USD ($)
|
Jun. 30, 2025
USD ($)
shares
|
Jun. 30, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
shares
|
Jun. 30, 2024
USD ($)
|
Dec. 31, 2025
USD ($)
|
Jun. 30, 2025
EUR (€)
shares
|
Dec. 31, 2024
USD ($)
|
Apr. 04, 2022
$ / shares
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| initial cash investment |
|
|
|
|
|
|
|
|
|
|
|
$ 10,515,812
|
|
$ 10,515,812
|
|
|
|
$ 8,297,223
|
|
| Options to acquire shares | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options remaining to be exercised | shares |
|
|
|
|
|
|
|
|
|
|
|
31,013
|
|
31,013
|
|
|
31,013
|
|
|
| BIAKOS License Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment for additional royalties |
|
|
|
|
|
|
|
|
|
|
|
$ 47,935
|
$ 42,305
|
$ 85,435
|
$ 77,305
|
|
|
|
|
| BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty percentage |
|
|
|
|
|
|
|
|
|
|
2.00%
|
|
|
|
|
|
|
|
|
| BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty percentage |
|
|
|
|
|
|
|
|
|
|
4.00%
|
|
|
|
|
|
|
|
|
| BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member] | Forecast [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Annual royalty |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 150,000
|
|
|
|
| BIAKOS Agreement [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment for additional royalties |
|
|
|
|
|
|
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
| ABF License Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase in royalty annual percentage |
|
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
| ABF License Agreement [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty percentage |
|
|
|
|
|
|
|
|
|
2.00%
|
|
|
|
|
|
|
|
|
|
| Payment for additional royalties |
|
|
|
|
|
|
|
|
|
$ 50,000
|
|
|
|
|
|
|
|
|
|
| ABF License Agreement [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty percentage |
|
|
|
|
|
|
|
|
|
4.00%
|
|
|
|
|
|
|
|
|
|
| Payment for additional royalties |
|
|
|
|
|
|
|
|
|
$ 75,000
|
|
|
|
|
|
|
|
|
|
| ABF License Agreement [Member] | Maximum [Member] | Product and Service, Other [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment for additional royalties |
|
|
|
|
|
|
|
|
|
$ 500,000
|
|
|
|
|
|
|
|
|
|
| Debrider License Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase in royalty annual percentage |
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
| Payment of cash or common stock due upon FDA clearance of certain licensed products |
|
|
|
|
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
|
| Debrider License Agreement [Member] | Rochal [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment of cash due upon FDA clearance of certain licensed products |
|
|
|
|
|
|
|
|
$ 500,000
|
|
|
|
|
|
|
|
|
|
|
| Debrider License Agreement [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty percentage |
|
|
|
|
|
|
|
|
2.00%
|
|
|
|
|
|
|
|
|
|
|
| Annual royalty |
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
| Debrider License Agreement [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty percentage |
|
|
|
|
|
|
|
|
4.00%
|
|
|
|
|
|
|
|
|
|
|
| Annual royalty |
|
|
|
|
|
|
|
|
$ 150,000
|
|
|
|
|
|
|
|
|
|
|
| Payment for additional royalties |
|
|
|
|
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
|
| BMI License Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalties percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00%
|
|
|
|
|
|
| Royalty payments year one |
|
|
|
|
|
|
|
|
|
|
|
100,000
|
|
$ 100,000
|
|
|
|
|
|
| Royalty payments year two |
|
|
|
|
|
|
|
|
|
|
|
200,000
|
|
200,000
|
|
|
|
|
|
| Royalty payments year three |
|
|
|
|
|
|
|
|
|
|
|
300,000
|
|
300,000
|
|
|
|
|
|
| initial cash investment | € |
|
€ 3.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible loan | € |
|
€ 1.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of ordinary shares issued | shares |
|
8,230
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding equity percentage |
|
6.67%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Additional contribution | € |
|
€ 4.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of exchange of additional ordinary shares | shares |
|
8,230
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity investment |
|
|
|
|
|
|
|
|
|
|
|
$ 2,400,000
|
|
$ 2,400,000
|
|
|
€ 2.0
|
|
|
| BMI License Agreement [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding equity percentage |
9.678%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of exchange of additional ordinary shares | shares |
4,116
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Precision Healing Merger Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash consideration |
|
|
|
|
|
|
|
$ 125,966
|
|
|
|
|
|
|
|
|
|
|
|
| Payment in cash |
|
|
|
|
|
|
|
$ 600,000
|
|
|
|
|
|
|
|
|
|
|
|
| Share price | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 30.75
|
| Options to acquire shares | shares |
|
|
|
|
|
|
|
144,191
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted exercise price | $ / shares |
|
|
|
|
|
|
|
$ 10.71
|
|
|
|
|
|
|
|
|
|
|
|
| Precision Healing Merger Agreement [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase shares | shares |
|
|
|
|
|
|
|
4,424
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price | $ / shares |
|
|
|
|
|
|
|
$ 7.32
|
|
|
|
|
|
|
|
|
|
|
|
| Expiration date |
|
|
|
|
|
|
|
Apr. 22, 2031
|
|
|
|
|
|
|
|
|
|
|
|
| Precision Healing Merger Agreement [Member] | Warrant One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase shares | shares |
|
|
|
|
|
|
|
12,301
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price | $ / shares |
|
|
|
|
|
|
|
$ 12.05
|
|
|
|
|
|
|
|
|
|
|
|
| Expiration date |
|
|
|
|
|
|
|
Aug. 10, 2030
|
|
|
|
|
|
|
|
|
|
|
|
| Precision Healing Merger Agreement [Member] | Accredited Investors [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance of shares | shares |
|
|
|
|
|
|
|
165,738
|
|
|
|
|
|
|
|
|
|
|
|
| Applied Asset Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Assets purchase price |
|
|
|
|
$ 15,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Installment payable |
|
|
|
|
2,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment of installment |
|
|
|
|
|
|
$ 625,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Applied Asset Purchase Agreement [Member] | Cash Closing Consideration [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash consideration paid |
|
|
|
|
$ 9,750,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Applied Asset Purchase Agreement [Member] | Stock Closing Consideration [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued as consideration | shares |
|
|
|
|
73,809
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Value of shares issued as consideration |
|
|
|
|
$ 3,000,000.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Applied Asset Purchase Agreement [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment of installment |
|
|
|
|
|
$ 625,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Applied Asset Purchase Agreement [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Earnout payable |
|
|
|
|
$ 10,000,000.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Services Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase agreement description |
|
|
|
|
As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000
per month during the term of the Petito Services Agreement, (ii) a royalty payment equal to 3% of the actual collections from net sales
of certain products the Owner develops or codevelops that reach commercialization, (iii) a royalty payment equal to 5% for the first
$50.0 million in aggregate collections from net sales of certain future products and a royalty payment of 2.5% on aggregate collections
from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv) $500,000 in cash in the
event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in cash in the event that a
U.S. patent is issued for a certain product; provided that with respect to the incentive payments described in (iv) and (v) of the foregoing,
the Owner shall not earn more than $2.5 million.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| License Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of unique collagen peptides | Integer |
|
|
|
18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding units percentage |
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| License Agreement [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment for additional royalties |
|
|
$ 50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty expense percentage |
|
|
|
1.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| License Agreement [Member] | Minimum [Member] | Royalty Agreement Terms [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment for additional royalties |
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| License Agreement [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty expense percentage |
|
|
|
3.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|